Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 20745-20746 [2021-08172]

Download as PDF 20745 khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 86, No. 75 / Wednesday, April 21, 2021 / Notices and ML in nuclear power industry operations and management, as well as potential pitfalls and challenges associated with their application. 1. What is status of the commercial nuclear power industry development or use of AI/ML tools to improve aspects of nuclear plant design, operations or maintenance or decommissioning? What tools are being used or developed? When are the tools currently under development expected to be put into use? 2. What areas of commercial nuclear reactor operation and management will benefit the most, and the least, from the implementation of AI/ML? Possible examples include, but are not limited to, inspection support, incident response, power generation, cybersecurity, predictive maintenance, safety/risk assessment, system and component performance monitoring, operational/ maintenance efficiency and shutdown management. 3. What are the potential benefits to commercial nuclear power operations of incorporating AI/ML in terms of (a) design or operational automation, (b) preventive maintenance trending, and (c) improved reactor operations staff productivity? 4. What AI/ML methods are either currently being used or will be in the near future in commercial nuclear plant management and operations? Example of possible AI/ML methods include, but are not limited to, artificial neural networks, decision trees, random forests, support vector machines, clustering algorithms, dimensionality reduction algorithms, data mining and content analytics tools, gaussian processes, Bayesian methods, natural language processing, and image digitization. 5. What are the advantages or disadvantages of a high-level, top-down strategic goal for developing and implementing AI/ML across a wide spectrum of general applications versus an ad-hoc, case-by-case targeted approach? 6. With respect to AI/ML, what phase of technology adoption is the commercial nuclear power industry currently experiencing and why? The current technology adoption model characterizes phases into categories such as: the innovator phase, the early adopter phase, the early majority phase, the late majority phase, and the laggard phase. 7. What challenges are involved in balancing the costs associated with the development and application of AI/ML tools, against plant operational and engineering benefits when integrating VerDate Sep<11>2014 18:12 Apr 20, 2021 Jkt 253001 AI/ML into operational decision-making and workflow management? 8. What is the general level of AI/ML expertise in the commercial nuclear power industry (e.g. expert, well-versed/ skilled, or beginner)? 9. How will AI/ML effect the commercial nuclear power industry in terms of efficiency, costs, and competitive positioning in comparison to other power generation sources? 10. Does AI/ML have the potential to improve the efficiency and/or effectiveness of nuclear regulatory oversight or otherwise affect regulatory costs associated with safety oversight? If so, in what ways? 11. AI/ML typically necessitates the creation, transfer and evaluation of very large amounts of data. What concerns, if any, exist regarding data security in relation to proprietary nuclear plant operating experience and design information that may be stored in remote, offsite networks? The teleconference meeting will be held on Thursday, May 27, 2021, 1:00 p.m. to 5:00 p.m. Eastern Daylight Time. DATES: Date May 27, 2021 ... Webinar information Link: https:// usnrc.webex.com Event number: 199 574 5068. Dated: April 15, 2021. For the Nuclear Regulatory Commission. Mehdi Reisi Fard, Chief, Performance and Reliability Branch, Division of Risk Analysis, Office of Nuclear Regulatory Research. Public Participation: The meeting will be held as a webinar using Cisco WebEx. Any member of the public who wishes to participate in any portion of this meeting should register in advance of the meeting by accessing the provided link above. Upon successful registration, a confirmation email will be generated providing the telephone bridge line and a link to join the webinar on the day of the meeting. Members of the public should also monitor the NRC’s Public Meeting Schedule at https://www.nrc.gov/pmns/ mtg for any meeting updates. If there are any questions regarding the meeting, persons should contact Ms. Jamerson using the information below. Contact Information: Kellee Jamerson, email: Kellee.Jamerson@nrc.gov, telephone: 301–415–7408. [FR Doc. 2021–08177 Filed 4–20–21; 8:45 am] Conduct of the Meeting BILLING CODE 7590–01–P The ACMUI Chair, Darlene F. Metter, M.D., will preside over the meeting. Dr. Metter will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting: 1. Persons who wish to provide a written statement should submit an electronic copy to Ms. Jamerson at the contact information listed above. All written statements must be received by May 24, 2021, three business days prior to the meeting, and must pertain to the topics on the agenda for the meeting. 2. Questions and comments from members of the public will be permitted during the meeting, at the discretion of the ACMUI Chairman. 3. The draft transcript and meeting summary will be available on ACMUI’s website https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/ 2021.html on or about July 9, 2021. 4. Persons who require special services, such as those for the hearing impaired, should notify Ms. Jamerson of their planned participation. This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission’s regulations in 10 CFR part 7. NUCLEAR REGULATORY COMMISSION Advisory Committee on the Medical Uses of Isotopes: Meeting Notice U.S. Nuclear Regulatory Commission. ACTION: Notice of Meeting. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) will convene a public teleconference meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on May 27, 2021, to discuss the NRC staff’s assessment of medical related events for fiscal year 2020 and the ACMUI Abnormal Occurrence Subcommittee’s draft report on the proposed limited revisions to abnormal occurrence criteria for medical events. The meeting agenda is subject to change. Meeting information, including a copy of the agenda and related documents, will be available on the ACMUI’s Meetings and Related Documents web page at https:// www.nrc.gov/reading-rm/doccollections/acmui/meetings/2021.html. The agenda and related meeting documents may also be obtained by contacting Ms. Kellee Jamerson using the information below. SUMMARY: PO 00000 Frm 00094 Fmt 4703 Sfmt 4703 E:\FR\FM\21APN1.SGM 21APN1 20746 Federal Register / Vol. 86, No. 75 / Wednesday, April 21, 2021 / Notices Dated at Rockville, Maryland, this 15th day of April 2021. For the U.S. Nuclear Regulatory Commission. Russell E. Chazell, Federal Advisory Committee Management Officer. [FR Doc. 2021–08172 Filed 4–20–21; 8:45 am] BILLING CODE 7590–01–P This notice identifies Schedule A, B, and C appointing authorities applicable to a single agency that were established or revoked from February 1, 2021 to February 28, 2021. SUMMARY: Julia Alford, Senior Executive Resources Services, Senior Executive Services and Performance Management, Employee Services, 202–606–2246. FOR FURTHER INFORMATION CONTACT: In accordance with 5 CFR 213.103, Schedule A, B, and C appointing authorities available for use by all agencies are codified in the Code of Federal Regulations (CFR). Schedule A, B, and C appointing authorities applicable to a single agency are not codified in the CFR, but the Office of Personnel Management (OPM) SUPPLEMENTARY INFORMATION: OFFICE OF PERSONNEL MANAGEMENT Excepted Service Office of Personnel Management (OPM). AGENCY: ACTION: Notice. publishes a notice of agency-specific authorities established or revoked each month in the Federal Register at www.gpo.gov/fdsys/. OPM also publishes an annual notice of the consolidated listing of all Schedule A, B, and C appointing authorities, current as of June 30, in the Federal Register. Schedule A No Schedule B Authorities to report during February 2021. Schedule B No Schedule B Authorities to report during February 2021. Schedule C The following Schedule C appointing authorities were approved during February 2021. Authorization No. Agency name Organization name Position title DEPARTMENT OF AGRICULTURE Office of the Assistant Secretary for Congressional Relations. Agricultural Marketing Service ....... Legislative Analyst .......................... DA210070 02/01/2021 Senior Advisor for Fair and Competitive Markets. Senior Policy Advisor ..................... Policy Advisor ................................. Senior Advisor for Data and Technology. Senior Policy Advisor ..................... Executive Assistant ........................ Senior Advisor (Upskilling and Broadband). Scheduler ....................................... DA210086 02/12/2021 DA210079 DA210089 DA210085 02/04/2021 02/23/2021 02/12/2021 DA210080 DC210081 DC210076 02/04/2021 02/05/2021 02/10/2021 DC210079 02/05/2021 Policy Advisor ................................. DC210083 02/05/2021 Deputy Director, Office of Policy and Strategic Planning. Senior Advisor ................................ Special Assistant ............................ Special Assistant (2) ...................... DC210086 02/10/2021 DC210087 DC210080 DD210191 DD210193 DD210204 02/25/2021 02/05/2021 02/12/2021 02/12/2021 02/18/2021 DD210173 DD210199 DD210175 DD210205 DD210194 DD210178 DD210186 DD210200 DD210170 DD210174 DD210189 DD210192 DD210177 02/02/2021 02/18/2021 02/02/2021 02/25/2021 02/12/2021 02/02/2021 02/12/2021 02/18/2021 02/02/2021 02/02/2021 02/12/2021 02/12/2021 02/02/2021 02/02/2021 02/02/2021 02/18/2021 02/16/2021 02/16/2021 02/16/2021 02/11/2021 02/11/2021 DEPARTMENT OF COMMERCE ... Farm Service Agency ..................... Foreign Agricultural Service ........... Office of the Assistant Secretary for Administration. Rural Utilities Service ..................... Immediate Office ............................ Office of Advance, Scheduling and Protocol. Office of Policy and Strategic Planning. DEPARTMENT OF DEFENSE ....... Office of the Deputy Secretary ....... Office of the Assistant Secretary of Defense (Legislative Affairs). Office of the Assistant to the Secretary of Defense (Public Affairs). Deputy Press Secretary ................. khammond on DSKJM1Z7X2PROD with NOTICES Director of Digital Media ................. Research Assistant ........................ Speechwriter (2) ............................. Office of the Secretary of Defense Deputy Director of Protocol ............ Special Assistant (3) ...................... Office of the Under Secretary of Defense (Acquisition and Sustainment). Special Assistant (4) ...................... Office of the Under Secretary of Defense (Personnel and Readiness). Office of the Under Secretary of Defense (Policy). Special Assistant ............................ AIR Office of the General Counsel ....... Attorney Advisor/Special Assistant DD210172 DD210180 DD210202 DF210007 DEPARTMENT OF THE ARMY ..... Office of the Secretary ................... Office of the Under Secretary ........ Office of the General Counsel ....... Office Assistant Secretary Army (Civil Works). Special Assistant ............................ Special Assistant ............................ Attorney Advisor ............................. Special Assistant ............................ DF210008 DF210009 DW210009 DW210010 DEPARTMENT FORCE. VerDate Sep<11>2014 OF THE 18:12 Apr 20, 2021 Jkt 253001 PO 00000 Frm 00095 Fmt 4703 Special Assistant (3) ...................... Sfmt 4703 E:\FR\FM\21APN1.SGM 21APN1 Effective date

Agencies

[Federal Register Volume 86, Number 75 (Wednesday, April 21, 2021)]
[Notices]
[Pages 20745-20746]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-08172]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Meeting 
Notice

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Notice of Meeting.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) will convene a 
public teleconference meeting of the Advisory Committee on the Medical 
Uses of Isotopes (ACMUI) on May 27, 2021, to discuss the NRC staff's 
assessment of medical related events for fiscal year 2020 and the ACMUI 
Abnormal Occurrence Subcommittee's draft report on the proposed limited 
revisions to abnormal occurrence criteria for medical events. The 
meeting agenda is subject to change. Meeting information, including a 
copy of the agenda and related documents, will be available on the 
ACMUI's Meetings and Related Documents web page at https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2021.html. The agenda and 
related meeting documents may also be obtained by contacting Ms. Kellee 
Jamerson using the information below.

DATES: The teleconference meeting will be held on Thursday, May 27, 
2021, 1:00 p.m. to 5:00 p.m. Eastern Daylight Time.

------------------------------------------------------------------------
                 Date                          Webinar information
------------------------------------------------------------------------
May 27, 2021..........................  Link: https://usnrc.webex.com
                                         Event number: 199 574 5068.
------------------------------------------------------------------------

    Public Participation: The meeting will be held as a webinar using 
Cisco WebEx. Any member of the public who wishes to participate in any 
portion of this meeting should register in advance of the meeting by 
accessing the provided link above. Upon successful registration, a 
confirmation email will be generated providing the telephone bridge 
line and a link to join the webinar on the day of the meeting. Members 
of the public should also monitor the NRC's Public Meeting Schedule at 
https://www.nrc.gov/pmns/mtg for any meeting updates. If there are any 
questions regarding the meeting, persons should contact Ms. Jamerson 
using the information below.
    Contact Information: Kellee Jamerson, email: 
[email protected], telephone: 301-415-7408.

Conduct of the Meeting

    The ACMUI Chair, Darlene F. Metter, M.D., will preside over the 
meeting. Dr. Metter will conduct the meeting in a manner that will 
facilitate the orderly conduct of business. The following procedures 
apply to public participation in the meeting:
    1. Persons who wish to provide a written statement should submit an 
electronic copy to Ms. Jamerson at the contact information listed 
above. All written statements must be received by May 24, 2021, three 
business days prior to the meeting, and must pertain to the topics on 
the agenda for the meeting.
    2. Questions and comments from members of the public will be 
permitted during the meeting, at the discretion of the ACMUI Chairman.
    3. The draft transcript and meeting summary will be available on 
ACMUI's website https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2021.html on or about July 9, 2021.
    4. Persons who require special services, such as those for the 
hearing impaired, should notify Ms. Jamerson of their planned 
participation.
    This meeting will be held in accordance with the Atomic Energy Act 
of 1954, as amended (primarily Section 161a); the Federal Advisory 
Committee Act (5 U.S.C. App); and the Commission's regulations in 10 
CFR part 7.


[[Page 20746]]


    Dated at Rockville, Maryland, this 15th day of April 2021.

    For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2021-08172 Filed 4-20-21; 8:45 am]
BILLING CODE 7590-01-P